✦ LIBER ✦

DEVELOPMENT AND CLINICAL VALIDATION OF A MULTIPLEX POLYMERASE CHAIN REACTION-DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE IDENTIFICATION OF FOODBORNE DIARRHEAGENIC ESCHERICHIA COLI

✍ Scribed by YIGANG XU; LICHUN CUI; SULONG LI; DANDAN LI; XINBO ZHANG; GUICHENG HUO

Book ID: 111343408
Publisher: Wiley (Blackwell Publishing)
Year: 2011
Tongue: English
Weight: 260 KB
Volume: 32
Category: Article
ISSN: 0149-6085
DOI: 10.1111/j.1745-4565.2011.00337.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Design and validation of a multiplex pol

Design and validation of a multiplex polymerase chain reaction for the identification of enterotoxigenic Escherichia coli and associated colonization factor antigens

✍ Rania A. Nada; Hind I. Shaheen; Iman Touni; Dina Fahmy; Adam W. Armstrong; Matth 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti